MEX-CD1
Wilson's Disease (Acute)
About MExbrain
MexBrain is a 2021 spin-off from the University of Lyon, pioneering a medical device approach to treating metal toxicity. Its core technology is MEX-CD1, a patented, non-absorbable polymer that chelates free metals during dialysis. The company is currently conducting two pilot clinical trials in Europe (MEXWILS and MEXACLF) and holds ISO 13485 certification for its device design and manufacturing. As a private, pre-revenue entity, it is positioned to address significant unmet needs in rare and acute diseases.
View full company profileAbout MExbrain
MexBrain is a 2021 spin-off from the University of Lyon, pioneering a medical device approach to treating metal toxicity. Its core technology is MEX-CD1, a patented, non-absorbable polymer that chelates free metals during dialysis. The company is currently conducting two pilot clinical trials in Europe (MEXWILS and MEXACLF) and holds ISO 13485 certification for its device design and manufacturing. As a private, pre-revenue entity, it is positioned to address significant unmet needs in rare and acute diseases.
View full company profile